Fondazione Emn Italy Onlus
Clinical trials sponsored by Fondazione Emn Italy Onlus, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Registry aims to map Real-World multiple myeloma care across italy Results expected Mar 2027 (estimated)
- Tailored Three-Drug combo targets Myeloma's toughest genetic weak spot Results expected Jul 2027 (estimated)
- Can a stronger drug cocktail give older myeloma patients a better start? Results expected Sep 2027 (estimated)
-
Can a stronger drug cocktail give older myeloma patients a better start?
Disease control OngoingResearchers are comparing two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. One group receives carfilzomib, lenalidomide and dexamethasone (KRd), and the other receives the standard lenalidomide and dexamethaso…
Phase 3 • Sponsor: Fondazione EMN Italy Onlus • Aim: Disease control
Last updated Sep 21, 2026 22:00 UTC
-
Tailored Three-Drug combo targets Myeloma's toughest genetic weak spot
Disease control OngoingResearchers are testing whether a combination of daratumumab, pomalidomide and dexamethasone can help people whose multiple myeloma has come back and carries a genetic change called del(17p). This change, found in about 10% of patients at diagnosis, makes the cancer harder to tre…
Phase 2 • Sponsor: Fondazione EMN Italy Onlus • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC